<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02902770</url>
  </required_header>
  <id_info>
    <org_study_id>2016-03-09</org_study_id>
    <nct_id>NCT02902770</nct_id>
  </id_info>
  <brief_title>Intravenous Lidocaine and Ketorolac for Pain Management</brief_title>
  <official_title>A Randomized Trial Comparing the Combination of Intravenous Lidocaine and Ketorolac to Either Analgesics Alone for ED Patients With Acute Renal Colic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antonios Likourezos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The literature regarding analgesic modalities, their combinations and routes of
      administrations for patients with pain related to renal colic is expanding. NSAID's (IV
      ketorolac) and opioids (morphine) constitutes the mainstay of treatment of renal colic either
      alone or in combinations. Despite their synergism and analgesic superiority when administered
      together, both classes of these medications possess a set of unfavorable side effects that
      limit their use. Emerging data of the use of IV lidocaine for patients with renal colic
      demonstrated good analgesic efficacy and safety profile. However, none of the trials directly
      compared lidocaine to ketorolac or the combination of both as viable options in patients
      unable to tolerate or to have serious contraindications to opioids. We designed a
      double-blinded, randomized, controlled trial to evaluate analgesic efficacy, safety and
      feasibility of non-opioid analgesics and their combinations in patients with renal colic. The
      hypothesis and proposed study will try to determine if a combination of IV lidocaine and
      reduced dose of IV ketorolac is superior to either drug alone and if this non-opioid
      analgesic modality is effective for controlling pain of renal colic origin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators designed a double-blind, randomized, clinical trial to evaluate analgesic
      efficacy, safety and feasibility of non-opioid analgesics IV Lidocaine and IV Ketorolac and
      combination of both in patients with renal colic. The hypothesis and proposed study will try
      to determine if a combination of IV lidocaine and IV ketorolac is superior to either drug
      alone and if this non-opioid analgesic combination is effective for controlling pain of renal
      colic origin. The trial will compare pain scores at 15 min and 30 min between and within the
      three treatment groups of the study: IV ketorolac 30mg push and 10 minute normal saline drip
      placebo, 1.5mg/kg IV lidocaine drip (given over 10 minutes) and normal saline push placebo,
      or IV ketorolac push and IV lidocaine drip.

      Once a patient is enrolled, the on duty ED pharmacist will prepare any one of the three
      treatment groups based on a predetermined randomization list generated via SPSS 19.0.The
      study investigators will record pain scores, vital signs, and side effects at baseline, 15,
      30 and 60 minutes post-medication administration. If the patient still reports pain of five
      or greater and requests additional pain relief then morphine at 0.1mg/kg will be given as the
      rescue analgesic. Blinding of medication from the patient, research team, and staff will be
      strictly maintained by the pharmacist investigators.

      Sample Size Calculation:

      Fifty per group or 150 is needed given a standard 1.3 as the minimum clinically significant
      score and 3.0 as our standard deviation at 80% power and a=.05.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">September 10, 2019</completion_date>
  <primary_completion_date type="Actual">October 4, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Score at 30 Minutes</measure>
    <time_frame>30 minutes</time_frame>
    <description>The trial will compare the patient's pain score on a 11 point Likert scale, ranging from 0 to 10 with 0 being no pain, 5 moderate pain and 10 very severe pain, at 30 minutes</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Lidocaine and normal saline push</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.5mg/kg IV Lidocaine Drip (given over 10 minutes) and normal saline push</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketorolac and normal saline drip</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV Ketorolac Tromethamine 30mg push and 10 minute normal saline drip</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine and Ketorolac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV Lidocaine Drip and IV Ketorolac Push</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>1.5 mg/kg IV lidocaine drip (given over 10 minutes)</description>
    <arm_group_label>Lidocaine and Ketorolac</arm_group_label>
    <arm_group_label>Lidocaine and normal saline push</arm_group_label>
    <other_name>Xylocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac Tromethamine</intervention_name>
    <description>IV ketorolac 30mg push</description>
    <arm_group_label>Ketorolac and normal saline drip</arm_group_label>
    <arm_group_label>Lidocaine and Ketorolac</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline Drip</intervention_name>
    <description>Normal Saline Drip Placebo given over 10 minutes</description>
    <arm_group_label>Ketorolac and normal saline drip</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline Push</intervention_name>
    <description>Normal Saline Push Placebo</description>
    <arm_group_label>Lidocaine and normal saline push</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Emergency Medicine Patient

          -  clinical diagnosis of acute renal colic

          -  pain score of &gt;=5 out of 10 on the numeric rating scale

          -  - age 18 - 64 years of age

        Exclusion Criteria:

          -  documented or suspected pregnancy, breastfeeding

          -  contraindication to nonsteroidal anti-inflammatory drugs or lidocaine

          -  known renal dysfunction

          -  received analgesics within 4 hours before presentation

          -  history of bleeding diathesis

          -  history of peptic ulcer disease

          -  current use of warfarin

          -  HR&lt;50 or &gt;150

          -  history of cardiac arrhythmias

          -  peritonitis or presence of any peritoneal sign

          -  altered mental status

          -  weight &gt; 100kg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergey Motov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <reference>
    <citation>Golzari SE, Soleimanpour H, Rahmani F, Zamani Mehr N, Safari S, Heshmat Y, Ebrahimi Bakhtavar H. Therapeutic approaches for renal colic in the emergency department: a review article. Anesth Pain Med. 2014 Feb 13;4(1):e16222. doi: 10.5812/aapm.16222. eCollection 2014 Feb.</citation>
    <PMID>24701420</PMID>
  </reference>
  <reference>
    <citation>Talati, J, Tiselius, H.-G, Albala, D.M, YE, Z. Urolithiasis: Basic Science and Clinical Practice. Springer Science &amp; Business Media, Dec 22, 2012</citation>
  </reference>
  <reference>
    <citation>Sandhu DP, Iacovou JW, Fletcher MS, Kaisary AV, Philip NH, Arkell DG. A comparison of intramuscular ketorolac and pethidine in the alleviation of renal colic. Br J Urol. 1994 Dec;74(6):690-3.</citation>
    <PMID>7827834</PMID>
  </reference>
  <reference>
    <citation>Larkin GL, Peacock WF 4th, Pearl SM, Blair GA, D'Amico F. Efficacy of ketorolac tromethamine versus meperidine in the ED treatment of acute renal colic. Am J Emerg Med. 1999 Jan;17(1):6-10.</citation>
    <PMID>9928687</PMID>
  </reference>
  <reference>
    <citation>O'Connor A, Schug SA, Cardwell H. A comparison of the efficacy and safety of morphine and pethidine as analgesia for suspected renal colic in the emergency setting. J Accid Emerg Med. 2000 Jul;17(4):261-4.</citation>
    <PMID>10921813</PMID>
  </reference>
  <reference>
    <citation>Safdar B, Degutis LC, Landry K, Vedere SR, Moscovitz HC, D'Onofrio G. Intravenous morphine plus ketorolac is superior to either drug alone for treatment of acute renal colic. Ann Emerg Med. 2006 Aug;48(2):173-81, 181.e1.</citation>
    <PMID>16953530</PMID>
  </reference>
  <reference>
    <citation>Catapano MS. The analgesic efficacy of ketorolac for acute pain. J Emerg Med. 1996 Jan-Feb;14(1):67-75. Review.</citation>
    <PMID>8655940</PMID>
  </reference>
  <reference>
    <citation>Castellsague J, Riera-Guardia N, Calingaert B, Varas-Lorenzo C, Fourrier-Reglat A, Nicotra F, Sturkenboom M, Perez-Gutthann S; Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1;35(12):1127-46. doi: 10.2165/11633470-000000000-00000. Review.</citation>
    <PMID>23137151</PMID>
  </reference>
  <reference>
    <citation>Duthie DJ, Nimmo WS. Adverse effects of opioid analgesic drugs. Br J Anaesth. 1987 Jan;59(1):61-77. Review.</citation>
    <PMID>2881564</PMID>
  </reference>
  <reference>
    <citation>Soleimanpour H, Hassanzadeh K, Mohammadi DA, Vaezi H, Esfanjani RM. Parenteral lidocaine for treatment of intractable renal colic: a case series. J Med Case Rep. 2011 Jun 29;5:256. doi: 10.1186/1752-1947-5-256.</citation>
    <PMID>21714904</PMID>
  </reference>
  <reference>
    <citation>Soleimanpour H, Hassanzadeh K, Vaezi H, Golzari SE, Esfanjani RM, Soleimanpour M. Effectiveness of intravenous lidocaine versus intravenous morphine for patients with renal colic in the emergency department. BMC Urol. 2012 May 4;12:13. doi: 10.1186/1471-2490-12-13.</citation>
    <PMID>22559856</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 5, 2016</study_first_submitted>
  <study_first_submitted_qc>September 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2016</study_first_posted>
  <results_first_submitted>February 26, 2020</results_first_submitted>
  <results_first_submitted_qc>March 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 18, 2020</results_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Maimonides Medical Center</investigator_affiliation>
    <investigator_full_name>Antonios Likourezos</investigator_full_name>
    <investigator_title>Research Manager</investigator_title>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Lidocaine</keyword>
  <keyword>Ketorolac</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 24, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT02902770/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lidocaine and Normal Saline Push</title>
          <description>1.5mg/kg IV Lidocaine Drip (given over 10 minutes) and normal saline push
Lidocaine: 1.5 mg/kg IV lidocaine drip (given over 10 minutes)
Normal Saline Push: Normal Saline Push Placebo</description>
        </group>
        <group group_id="P2">
          <title>Ketorolac and Normal Saline Drip</title>
          <description>IV Ketorolac Tromethamine 30mg push and 10 minute normal saline drip
Ketorolac Tromethamine: IV ketorolac 30mg push
Normal Saline Drip: Normal Saline Drip Placebo given over 10 minutes</description>
        </group>
        <group group_id="P3">
          <title>Lidocaine and Ketorolac</title>
          <description>IV Lidocaine Drip and IV Ketorolac Push
Lidocaine: 1.5 mg/kg IV lidocaine drip (given over 10 minutes)
Ketorolac Tromethamine: IV ketorolac 30mg push</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lidocaine and Normal Saline Push</title>
          <description>1.5mg/kg IV Lidocaine Drip (given over 10 minutes) and normal saline push
Lidocaine: 1.5 mg/kg IV lidocaine drip (given over 10 minutes)
Normal Saline Push: Normal Saline Push Placebo</description>
        </group>
        <group group_id="B2">
          <title>Ketorolac and Normal Saline Drip</title>
          <description>IV Ketorolac Tromethamine 30mg push and 10 minute normal saline drip
Ketorolac Tromethamine: IV ketorolac 30mg push
Normal Saline Drip: Normal Saline Drip Placebo given over 10 minutes</description>
        </group>
        <group group_id="B3">
          <title>Lidocaine and Ketorolac</title>
          <description>IV Lidocaine Drip and IV Ketorolac Push
Lidocaine: 1.5 mg/kg IV lidocaine drip (given over 10 minutes)
Ketorolac Tromethamine: IV ketorolac 30mg push</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="50"/>
            <count group_id="B4" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.3" spread="11.0"/>
                    <measurement group_id="B2" value="42.3" spread="10.5"/>
                    <measurement group_id="B3" value="41.9" spread="10.4"/>
                    <measurement group_id="B4" value="41.9" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Score at 30 Minutes</title>
        <description>The trial will compare the patient's pain score on a 11 point Likert scale, ranging from 0 to 10 with 0 being no pain, 5 moderate pain and 10 very severe pain, at 30 minutes</description>
        <time_frame>30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine and Normal Saline Push</title>
            <description>1.5mg/kg IV Lidocaine Drip (given over 10 minutes) and normal saline push
Lidocaine: 1.5 mg/kg IV lidocaine drip (given over 10 minutes)
Normal Saline Push: Normal Saline Push Placebo</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac and Normal Saline Drip</title>
            <description>IV Ketorolac Tromethamine 30mg push and 10 minute normal saline drip
Ketorolac Tromethamine: IV ketorolac 30mg push
Normal Saline Drip: Normal Saline Drip Placebo given over 10 minutes</description>
          </group>
          <group group_id="O3">
            <title>Lidocaine and Ketorolac</title>
            <description>IV Lidocaine Drip and IV Ketorolac Push
Lidocaine: 1.5 mg/kg IV lidocaine drip (given over 10 minutes)
Ketorolac Tromethamine: IV ketorolac 30mg push</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score at 30 Minutes</title>
          <description>The trial will compare the patient's pain score on a 11 point Likert scale, ranging from 0 to 10 with 0 being no pain, 5 moderate pain and 10 very severe pain, at 30 minutes</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.52" spread="3.07"/>
                    <measurement group_id="O2" value="3.88" spread="2.92"/>
                    <measurement group_id="O3" value="3.14" spread="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lidocaine and Normal Saline Push</title>
          <description>1.5mg/kg IV Lidocaine Drip (given over 10 minutes) and normal saline push
Lidocaine: 1.5 mg/kg IV lidocaine drip (given over 10 minutes)
Normal Saline Push: Normal Saline Push Placebo</description>
        </group>
        <group group_id="E2">
          <title>Ketorolac and Normal Saline Drip</title>
          <description>IV Ketorolac Tromethamine 30mg push and 10 minute normal saline drip
Ketorolac Tromethamine: IV ketorolac 30mg push
Normal Saline Drip: Normal Saline Drip Placebo given over 10 minutes</description>
        </group>
        <group group_id="E3">
          <title>Lidocaine and Ketorolac</title>
          <description>IV Lidocaine Drip and IV Ketorolac Push
Lidocaine: 1.5 mg/kg IV lidocaine drip (given over 10 minutes)
Ketorolac Tromethamine: IV ketorolac 30mg push</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Antonios Likourezos</name_or_title>
      <organization>Maimonides Medical Center</organization>
      <phone>7182836896</phone>
      <email>alikourezos@maimonidesmed.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

